A new combination therapy has shown significant promise for treating metastatic uveal melanoma, a rare and aggressive form of eye cancer that has historically lacked effective treatment options. In a major clinical trial, patients receiving darovasertib plus crizotinib experienced a median progression-free survival of 6.9 months compared to 3.1 months with standard care, representing a 58% reduction in the risk of disease progression .

What Is Uveal Melanoma and Why Is It So Difficult to Treat?

Uveal melanoma is a cancer that develops in the uvea, the pigmented layer of the eye. Unlike the more common cutaneous melanoma that develops on the skin, uveal melanoma is particularly aggressive and often spreads to other parts of the body, especially the liver. The disease carries a poor prognosis, with patients historically surviving only 10 to 12 months after metastasis . Until now, there have been no approved therapies specifically designed for patients who are HLA-A*02:01 negative, a genetic marker that affects how their immune system responds to treatment.

This genetic distinction matters because it determines which immunotherapy approaches will work. Patients who are HLA-A*02:01 negative have been left with limited options, often receiving off-label treatments or standard chemotherapy that provided minimal benefit. The new trial results offer hope for this underserved population.

How Do These New Drugs Work Together?

The combination therapy uses two different mechanisms to attack cancer cells. Darovasertib is a protein kinase C (PKC) inhibitor that targets specific mutations found in uveal melanoma cells. Crizotinib, also known by its brand name Xalkori, is a targeted therapy that inhibits the MET protein, which helps cancer cells survive and grow. By combining these two drugs, researchers found they could achieve better results than either drug alone or standard treatments.

The trial enrolled approximately 420 patients who were randomly assigned to receive either the combination therapy or investigator's choice of standard treatment, which included pembrolizumab (Keytruda), ipilimumab (Yervoy) plus nivolumab (Opdivo), or dacarbazine . This design allowed researchers to compare the new approach directly against the best available alternatives.

What Do the Trial Numbers Actually Show?

The results from the OptimUM-02 trial are striking. Patients receiving darovasertib plus crizotinib had an overall response rate of 37.1%, meaning more than one-third of patients experienced tumor shrinkage . The trial documented 5 complete responses, where tumors disappeared entirely, compared to zero complete responses in the standard treatment group. The median duration of response was 6.8 months, indicating that benefits lasted a meaningful length of time.

Earlier phase 1/2 trial results presented in October 2025 showed even more encouraging long-term outcomes. The median overall survival, which measures how long patients lived after starting treatment, was 21.1 months in the combination therapy arm compared to 10 to 12 months with historical controls . This represents roughly a doubling of survival time for patients with this previously untreatable cancer.

What Side Effects Should Patients Expect?

Like all cancer treatments, the combination therapy comes with side effects. However, most were manageable and not severe. The most common side effects included:

• Gastrointestinal Issues: Diarrhea occurred in 90.9% of patients but was severe (grade 3 or higher) in only 2.3%. Nausea affected 79.5% of patients with no severe cases, and vomiting occurred in 47.7% with no severe cases.
• Skin and Fluid Changes: Acneiform dermatitis (a rash resembling acne) developed in 43.2% of patients, and peripheral edema (swelling in the limbs) occurred in 61.4%, neither with severe cases.
• Metabolic Effects: Low blood protein levels (hypoalbuminemia) occurred in 43.2% of patients with severe cases in 2.3%, and fatigue affected 38.6% with no severe cases.

The side effect profile is notably different from traditional chemotherapy, with most effects being manageable rather than life-threatening. This makes the treatment more tolerable for patients already dealing with a serious cancer diagnosis.

When Will This Treatment Become Available?

The pharmaceutical companies IDEAYA Biosciences and Servier announced plans to submit a new drug application in the second half of 2026 based on additional details from the OptimUM-02 trial . This means the treatment could potentially be available to patients within the next year or so, pending regulatory approval. The timing is significant because uveal melanoma patients currently have few effective options and often face rapid disease progression.

"Metastatic uveal melanoma is an area of high unmet medical need with poor prognosis and short overall survival, and there are currently no approved therapies for HLA-A*02:01-negative patients with metastatic uveal melanoma. The data from the OptimUM-02 study provides potential practice changing results for the treatment of first-line metastatic uveal melanoma," stated Meredith McKean, MD, MPH, director of the Melanoma and Skin Cancer Research Program at Sarah Cannon Research Institute.

Meredith McKean, MD, MPH, Director of the Melanoma and Skin Cancer Research Program at Sarah Cannon Research Institute

What This Means for Patients and the Future of Melanoma Treatment

This breakthrough represents a significant shift in how doctors approach uveal melanoma. For decades, patients with this rare cancer had limited options and poor outcomes. The new combination therapy offers the first targeted approach specifically designed for HLA-A*02:01-negative patients, addressing a gap that has left many patients without effective treatment.

The success of this approach also highlights the importance of understanding genetic differences in cancer. By identifying that certain patients have specific mutations and genetic markers, researchers can develop treatments tailored to those characteristics. This precision medicine approach is becoming increasingly common in cancer care, moving away from one-size-fits-all chemotherapy toward treatments designed for specific patient populations.

For patients currently diagnosed with metastatic uveal melanoma, these results offer hope. While the treatment is not yet available, the strong trial data suggests that approval is likely, and patients may soon have access to a therapy that could significantly extend their survival and improve their quality of life. Patients should discuss these developments with their oncologists to understand whether they might be candidates for this treatment once it becomes available.